Bioinformatics Analysis and Experimental Validation of ASF1B in Breast Tumors
Cancer Medicine · 2025-09 · 14 (18)
DOI: 10.1002/cam4.71073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 13.09.2025. Verfasst von Wenhao Xing und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Cell Cycle Proteins, Computational Biology, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cultivation of Young and Middle-aged Talents in Health Science and Technology Innovation, Program for Tackling Key Problems in Medical Science and Technology.
Abstract (Originalsprache)
Objective
To investigate the association between ASF1B expression and pathological characteristics of breast cancer, and to further explore its role in tumor progression and the immune microenvironment, thereby evaluating its potential as a therapeutic target.
Methods
ASF1B expression in breast cancer was analyzed using the GEPIA2 and BEST databases. Its association with patient prognosis was assessed using Kaplan–Meier survival analysis. Protein co‐expression networks were constructed using GeneMANIA. The correlation between ASF1B expression and immune cell infiltration was evaluated through the TIMER platform. Experimental validation was performed using qPCR and immunohistochemistry (IHC) on 67 breast cancer tissue samples.
Results
ASF1B expression was significantly elevated in breast cancer tissues compared to normal tissues ( p < 0.05). High ASF1B expression was associated with reduced overall and recurrence‐free survival ( p < 0.05). Protein interaction analysis revealed that ASF1B was strongly linked to proteins involved in DNA replication, cell cycle progression, and chromatin remodeling. Immune analysis indicated positive correlations with B cells, neutrophils, and dendritic cells and a negative correlation with macrophage infiltration ( p < 0.05). Clinical data further showed that high ASF1B expression was significantly associated with HER2‐positive breast cancer ( p = 0.026).
Conclusion
ASF1B is highly expressed in breast cancer and correlates with poor prognosis and immune cell infiltration. It may serve as a potential prognostic biomarker and therapeutic target in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
ORCID-Profile: Wenhao Xing, Wendong Wang
Förderung
- Cultivation of Young and Middle-aged Talents in Health Science and Technology Innovation
- Program for Tackling Key Problems in Medical Science and Technology
Zitieren
APA
Xing, W., Deng, M., Wang, W., Liu, Y., Mi, X., Li, H., & Ge, X. (2025). Bioinformatics Analysis and Experimental Validation of ASF1B in Breast Tumors. Cancer Medicine, 14(18). https://doi.org/10.1002/cam4.71073
Vancouver
Xing W, Deng M, Wang W, Liu Y, Mi X, Li H, et al. Bioinformatics Analysis and Experimental Validation of ASF1B in Breast Tumors. Cancer Medicine. 2025;14(18). doi:10.1002/cam4.71073
BibTeX
@article{Xing2025,
author = {Xing, Wenhao and Deng, Meng and Wang, Wendong and Liu, Yueqi and Mi, Xuefang and Li, Huixia and Ge, Xin},
title = {Bioinformatics Analysis and Experimental Validation of ASF1B in Breast Tumors},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {18},
doi = {10.1002/cam4.71073}
}
EUVIMED